HC Wainwright Lowers Earnings Estimates for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at HC Wainwright lowered their Q2 2025 earnings estimates for Cytokinetics in a report released on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($1.47) for the quarter, down from their previous estimate of ($1.44). HC Wainwright currently has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.52) EPS and FY2025 earnings at ($5.80) EPS.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $2.77 million. The firm’s quarterly revenue was up 89.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.33) earnings per share.

A number of other research analysts have also recently weighed in on CYTK. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price target on the stock. Bank of America reduced their price objective on Cytokinetics from $62.00 to $54.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 15th. Needham & Company LLC reissued a “buy” rating and set a $72.00 price target on shares of Cytokinetics in a research report on Friday, May 2nd. JMP Securities reaffirmed a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research report on Thursday, April 10th. Finally, Royal Bank of Canada dropped their price objective on shares of Cytokinetics from $82.00 to $80.00 and set an “outperform” rating on the stock in a research note on Wednesday. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average target price of $74.44.

Cytokinetics Price Performance

CYTK stock opened at $31.69 on Friday. The company has a market cap of $3.78 billion, a PE ratio of -5.89 and a beta of 0.81. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The stock has a 50-day moving average price of $40.18 and a two-hundred day moving average price of $45.96. Cytokinetics has a 12-month low of $31.67 and a 12-month high of $63.46.

Institutional Investors Weigh In On Cytokinetics

A number of hedge funds have recently added to or reduced their stakes in CYTK. Jones Financial Companies Lllp increased its holdings in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 374 shares during the period. Centricity Wealth Management LLC bought a new position in Cytokinetics in the 4th quarter worth about $29,000. Fifth Third Bancorp increased its stake in shares of Cytokinetics by 42.2% in the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 291 shares during the period. Parallel Advisors LLC raised its holdings in shares of Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 916 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Cytokinetics by 281.0% in the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 826 shares in the last quarter.

Insider Buying and Selling at Cytokinetics

In related news, EVP Andrew Callos sold 3,341 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total value of $144,565.07. Following the sale, the executive vice president now owns 64,434 shares of the company’s stock, valued at approximately $2,788,059.18. This trade represents a 4.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total value of $91,960.00. Following the transaction, the executive vice president now owns 116,071 shares of the company’s stock, valued at approximately $5,336,944.58. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 95,362 shares of company stock worth $3,899,118 over the last quarter. 2.70% of the stock is owned by corporate insiders.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.